Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1:9:882717.
doi: 10.3389/fnut.2022.882717. eCollection 2022.

Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial

A-Ra Cho  1 , Kyung-Won Hong  2 , Yu-Jin Kwon  3 , Ja-Eun Choi  2 , Hye-Sun Lee  4 , Hyung-Mi Kim  5 , Soong June Bae  6 , Sung Gwe Ahn  6 , Joon Jeong  6 , Ji-Won Lee  7
Affiliations

Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial

A-Ra Cho et al. Front Nutr. .

Abstract

Background and aims: Weight management is recommended in overweight or obese breast cancer patients, as they have an increased risk of cancer recurrence and poor prognosis. Furthermore, identifying the relationships between genetic factors and nutrition could help suggest possible individualized nutritional solutions in weight management. The objective of this pilot randomized controlled trial was to investigate the influence of two obesity-associated single nucleotide polymorphisms and the Mediterranean diet intervention on weight loss and modification of nutrient intake and metabolic parameters in overweight or obese, postmenopausal, breast cancer patients receiving adjuvant hormone therapy.

Methods: Seventy-eight breast cancer patients were randomly assigned to the Mediterranean diet (MeDiet) group or control group, and seventy-one were finally analyzed. Body composition, nutrient intake, and metabolic parameters were assessed at baseline and after the 8-week intervention. Fat mass and obesity-associated (FTO) rs7185735 and melanocortin-4 receptor (MC4R) rs476828 variants were genotyped.

Results: We found that both variants did not influence weight loss or improvement of metabolic parameters within the Mediterranean diet intervention. Intake of saturated fatty acid (SFA) and trans fat was significantly increased in C carriers compared with the TT genotype of MC4R rs476828 only in the control group (p = 0.002 for SFA; p = 0.016 for trans fat), whereas no significant difference was observed between genotypes in the MeDiet group. There were statistically significant interactions between MC4R rs476828 and dietary intervention for changes in SFA intake (p = 0.009) and trans fat intake (p = 0.049).

Conclusion: Our data suggest that considering the effects of genotype may be more necessary when the Mediterranean diet is not followed and that this diet may have a protective role against the effects of certain genotypes. Further studies are required to determine the potential mechanism of the observed gene-diet interaction.

Clinical trial registration: [www.ClinicalTrials.gov], identifier [NCT04045392].

Keywords: FTO gene; MC4R gene; Mediterranean diet; breast cancer; nutrigenetics.

PubMed Disclaimer

Conflict of interest statement

K-WH and J-EC were employed by Theragen Etex Bio Institute Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study participant selection process.
FIGURE 2
FIGURE 2
Gene-diet interactions between the MC4R rs476828 variant and dietary intervention for changes in (A) saturated fatty acid (SFA) intake and (B) trans fat intake.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, et al. Recurrence dynamics of breast cancer according to baseline body mass index. Eur J Cancer. (2017) 87:10–20. 10.1016/j.ejca.2017.10.007 - DOI - PubMed
    1. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. (2017) 67:378–97. 10.3322/caac.21405 - DOI - PMC - PubMed
    1. Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. J Steroid Biochem Mol Biol. (2015) 153:35–44. 10.1016/j.jsbmb.2015.07.008 - DOI - PubMed
    1. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. (2015) 1:611–21. 10.1001/jamaoncol.2015.1546 - DOI - PMC - PubMed
    1. Robinson PJ, Bell RJ, Davis SR. Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. Maturitas. (2014) 79:279–86. - PubMed

Associated data